ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Assessing financial toxicity with COST-FACIT: experience from a tertiary care cancer center.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFinancial toxicity (FT) refers to the direct and indirect consequences of cancer diagnosis and treatment and is a key mediator of quality of life (QOL) and survival in cancer patients. To address this, financial navigation (FN) programs have been implemented in many cancer centers. At our large tertiary care cancer center, the FN program uses the Comprehensive Score for Financial Toxicity (COST) to screen patients undergoing first cancer treatment. We aimed to better understand FT, risk factors, and association with outcomes in our cancer population.
methodsWe identified 1906 patients with any cancer diagnosis and a completed COST between 6/2021 and 2/2024. Sociodemographic data including the Area Deprivation Index (ADI), disease, and treatment characteristics as well as patient-reported outcomes (PROMIS10, PHQ9 and NCCN DT) were collected. Risk factors for FT and association of FT on overall survival (OS) were analyzed.
resultsMedian age was 65 years (IQR 56-72); 54% female, 82% white, 57% married, 47% insured privately, and 35% with Medicare. Younger age, race/ethnicity, insurance type, tobacco use, and higher ADI were associated with higher FT. Higher distress (NCCN DT, N = 1001) and lower physical (N = 1474) and mental (N = 1505) health (PROMIS10) were also associated with higher FT. FT was not associated with time to treat (TTT) or OS. However, higher ADI was significantly associated with TTT (HR 0.98, 95% CI 0.96-1.00, p = 0.04) but not OS.
conclusionsOur study provides insights into risk factors for FT in a large cancer population. We did not demonstrate a significant association of FT on survival. Further analysis in specific disease groups is needed to better understand these relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.